ALGS

Aligos Therapeutics, Inc. (ALGS) | Rumor.io

Aligos Therapeutics

ALGS

Attention (50-day avg)0%

Attention rank (50-day avg)#3,492

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.18

Market capitalization34.6M

Earnings per share-7.71

Dividend yield (TTM)—

Revenue (annual)2.2M

Net income (annual)-24.2M

Social

What share of all stock conversation is about ALGS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% -0.02

Jul 8

Aligos Therapeutics, Inc. ($ALGS) is on a steady upward trend, with a potential pump expected after 1:30 EST.
The stock has a chance to increase by $20 or more before 8pm, with a potential target price of $80.
Analysts have given price targets of up to $175, with the current price being considered a good time to accumulate.

Generated by AI

Sentiment

Of the messages about ALGS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	88.14% -6.82
Bearish	0%	0%	0% 0	11.86% +6.82

Bullish· Jul 6

The company has received a significant cash infusion of $25M, which is a non-dilutive source of funding and could lead to a stock price increase to $37.
The company has a high institutional holder percentage of 55%, indicating strong support from large investors.
The company is eligible to receive up to $420 million in milestone payments plus royalties on net sales under a recent agreement, making $10 a possible stock price target.

Bearish· Apr 17

The company's stock price may be due for a correction, as it has historically doubled in price only to subsequently decline by nearly 50% in a short period of time.
Market makers may be accumulating shares of the company, potentially indicating a bearish sentiment from institutional investors.
The company's recent strong volume and lack of price movement may suggest that institutions are dumping shares ahead of a major catalyst, such as upcoming data releases.

Generated by AI

Topics

Of the messages about ALGS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	61.8%
Earnings	0%	0%	0%	0.86%
Analysts	0%	0%	0%	11.8%
Controversies	0%	0%	0%	7.51%
Technical Analysis	0%	0%	0%	17.81%
Macro	0%	0%	0%	0.21%

Analysts· Jan 7

SVB Leerink analyst Roanna Ruiz maintains Aligos Therapeutics with an Outperform rating and lowers the price target from $29 to $15.
JP Morgan downgraded Aligos Therapeutics to Neutral from Overweight and lowered its price target from $30 to $12.
JP Morgan analyst Eric Joseph downgraded Aligos Therapeutics from Overweight to Neutral and lowered the price target from $30 to $12.

Announcements· Apr 16

Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium in Greater China for chronic hepatitis B virus infection.
The agreement includes an upfront payment of $25 million, up to $420 million in clinical, regulatory, and sales milestones, and tiered, high single-digit royalties on net sales in Amoytop's licensed territories.
The deal is expected to extend Aligos' cash runway into Q4 2026 and leverage Amoytop's hepatology market strength to bring a new hepatitis B drug to China, boosting cash and speeding access for millions of patients.

Generated by AI

Community

Of the messages about ALGS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	22.96%
Newcomers	100%	100%	100%	77.04%

Regulars· Feb 14

Several regular participants are anticipating $ALGS to reach $23.20, with some expecting it to break through to $26 or higher.
There is a strong sentiment among these regulars that $ALGS will continue to rise and potentially take out its old highs, with some predicting a move up to $40 or more.
The participants are adding to their positions, with many expressing excitement and anticipation about the potential for a breakout and a measured move above the current price.

Newcomers· Apr 16

The stock price of Aligos Therapeutics, Inc. ($ALGS) surged 20% after announcing an exclusive license agreement with Amoytop to develop and commercialize a hepatitis B drug in Greater China.
The agreement includes a $25M upfront payment, up to $420M in milestones, and tiered high single-digit royalties, providing near-term financial stability and de-risking Aligos' development program.
The deal is expected to have a significant impact on Aligos' stock price, with traders monitoring Amoytop's share price and considering options for the potential move.

Generated by AI

News

Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement

Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.

14d agoThe Globe and Mail

Aligos Therapeutics at Cantor Fitzgerald conference: hbv pipeline in focus

20d agoInvesting.com

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference. Cantor Global Healthcare Conference Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET The presentation will premiere at the time listed above

27d agoYahoo Finance

Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates

Aligos Therapeutics (NASDAQ:ALGS) shares rose 7. 6% to $6.

28d agoYahoo Finance

Why is Aligos Therapeutics stock rallying 7% today?

28d agoInvesting.com

Aligos begins phase 1 trial of hepatitis B treatment in China

1mo agoInvesting.com

Also Discussed

Investors talking about ALGS also mention

#	Name	Attention
1	RVPH - Reviva Pharmaceuticals Holdings, Inc.	——
2	Sagimet Biosciences Inc. Series A Common StockSGMT	0%0
3	ACHL - Achilles Therapeutics plc	——
4	Nexalin Technology, Inc. Common StockNXL	0%0
5	Calidi Biotherapeutics, Inc.CLDI	0%0
6	BioVie Inc.BIVI	0%0
7	Instil Bio Inc.TIL	0%0
8	Precision BioSciences, Inc.DTIL	0%new
9	Innoviz Technologies Ltd.INVZ	0%+0
10	Future Vision II Acquisition Corp.FVN	0%new

Aligos Therapeutics, Inc.

Healthcare
Biotechnology

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver diseases and viral infections. The company’s current programs target chronic hepatitis B, metabolic dysfunction-associated steatohepatitis, and coronavirus-related infections, using small-molecule and oligonucleotide approaches. Its pipeline includes investigational candidates designed to address unmet medical needs in these disease areas, with emphasis on antiviral activity and liver-disease biology. Aligos Therapeutics also works through research collaborations and licensing arrangements that support development of selected programs. Based in South San Francisco, California, Aligos Therapeutics operates within the biotechnology sector as a drug-development company centered on advancing therapies from discovery through clinical evaluation.

Website

Location

One Corporate Drive

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about ALGS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% -0.02

Jul 8

Aligos Therapeutics, Inc. ($ALGS) is on a steady upward trend, with a potential pump expected after 1:30 EST.
The stock has a chance to increase by $20 or more before 8pm, with a potential target price of $80.
Analysts have given price targets of up to $175, with the current price being considered a good time to accumulate.

Generated by AI

Sentiment

Of the messages about ALGS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	88.14% -6.82
Bearish	0%	0%	0% 0	11.86% +6.82

Bullish· Jul 6

The company has received a significant cash infusion of $25M, which is a non-dilutive source of funding and could lead to a stock price increase to $37.
The company has a high institutional holder percentage of 55%, indicating strong support from large investors.
The company is eligible to receive up to $420 million in milestone payments plus royalties on net sales under a recent agreement, making $10 a possible stock price target.

Bearish· Apr 17

The company's stock price may be due for a correction, as it has historically doubled in price only to subsequently decline by nearly 50% in a short period of time.
Market makers may be accumulating shares of the company, potentially indicating a bearish sentiment from institutional investors.
The company's recent strong volume and lack of price movement may suggest that institutions are dumping shares ahead of a major catalyst, such as upcoming data releases.

Generated by AI

Topics

Of the messages about ALGS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	61.8%
Earnings	0%	0%	0%	0.86%
Analysts	0%	0%	0%	11.8%
Controversies	0%	0%	0%	7.51%
Technical Analysis	0%	0%	0%	17.81%
Macro	0%	0%	0%	0.21%

Analysts· Jan 7

SVB Leerink analyst Roanna Ruiz maintains Aligos Therapeutics with an Outperform rating and lowers the price target from $29 to $15.
JP Morgan downgraded Aligos Therapeutics to Neutral from Overweight and lowered its price target from $30 to $12.
JP Morgan analyst Eric Joseph downgraded Aligos Therapeutics from Overweight to Neutral and lowered the price target from $30 to $12.

Announcements· Apr 16

Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium in Greater China for chronic hepatitis B virus infection.
The agreement includes an upfront payment of $25 million, up to $420 million in clinical, regulatory, and sales milestones, and tiered, high single-digit royalties on net sales in Amoytop's licensed territories.
The deal is expected to extend Aligos' cash runway into Q4 2026 and leverage Amoytop's hepatology market strength to bring a new hepatitis B drug to China, boosting cash and speeding access for millions of patients.

Generated by AI

Community

Of the messages about ALGS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	22.96%
Newcomers	100%	100%	100%	77.04%

Regulars· Feb 14

Several regular participants are anticipating $ALGS to reach $23.20, with some expecting it to break through to $26 or higher.
There is a strong sentiment among these regulars that $ALGS will continue to rise and potentially take out its old highs, with some predicting a move up to $40 or more.
The participants are adding to their positions, with many expressing excitement and anticipation about the potential for a breakout and a measured move above the current price.

Newcomers· Apr 16

The stock price of Aligos Therapeutics, Inc. ($ALGS) surged 20% after announcing an exclusive license agreement with Amoytop to develop and commercialize a hepatitis B drug in Greater China.
The agreement includes a $25M upfront payment, up to $420M in milestones, and tiered high single-digit royalties, providing near-term financial stability and de-risking Aligos' development program.
The deal is expected to have a significant impact on Aligos' stock price, with traders monitoring Amoytop's share price and considering options for the potential move.

Generated by AI

Aligos Therapeutics

Social

Jul 8

Bullish· Jul 6

Bearish· Apr 17

Analysts· Jan 7

Announcements· Apr 16

Regulars· Feb 14

Newcomers· Apr 16

Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement

Aligos Therapeutics at Cantor Fitzgerald conference: hbv pipeline in focus

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates

Why is Aligos Therapeutics stock rallying 7% today?

Aligos begins phase 1 trial of hepatitis B treatment in China

Also Discussed

Aligos Therapeutics, Inc.

Company Information

Location

Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement

Aligos Therapeutics at Cantor Fitzgerald conference: hbv pipeline in focus

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates

Why is Aligos Therapeutics stock rallying 7% today?

Aligos begins phase 1 trial of hepatitis B treatment in China

Also Discussed

Social

Jul 8

Bullish· Jul 6

Bearish· Apr 17

Analysts· Jan 7

Announcements· Apr 16

Regulars· Feb 14

Newcomers· Apr 16